ЭЗОМЕПРАЗОЛ В ЛЕЧЕНИИ ГАСТРОЭЗОФАГЕАЛЬНОЙ РЕФЛЮКСНОЙ БОЛЕЗНИ У ДЕТЕЙ И ПОДРОСТКОВ
Аннотация
Ключевые слова: дети, подростки, гастроэзофагеальная рефлюксная болезнь, эзомепразол, лечение.
(Вопросы современной педиатрии. – 2008;7(4):132-135)
Список литературы
1. Лазебник Л.Б., Васильев Ю.В., Мананников И.В. Гастроэзофагеальная рефлюксная болезнь: эпидемиология, клинические аспекты, вопросы лечения. Справочник поликлинического врача. 2005; 3: 23–28.
2. Кислотозависимые состояния у детей. Под ред. В.А. Таболина. М. 1999.
3. Chitkara D.K., Talley N.J., Weaver A.L. et al. Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort study. Clin. Gastroenterol. Hepatol. 2007; 5 (2): 186–191.
4. Лярская Н.В. Частота и распространенность неэрозивной и эрозивной гастроэзофагеальной рефлюксной болезни у детей. Материалы XIV Конгресса детских гастроэнтерологов России. М. 2007.
5. El-Serag H.B., Gilger M., Carter J. tt al. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am. J. Gastroenterol. 2004; 99 (5): 806–812.
6. Canani R.B., Cirillo P., Roggero P. et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006; 117 (5): 817–820.
7. Gold B.D. Is gastroesophageal reflux disease really a life long disease: do babies who regurgitate grow up to be adults with GERD complications? Am. J. Gastroenterol. 2006; 101: 641–644.
8. Youssef N.N., Murphy T.G., Langseder A.L., Rosh J.R. Quality of life for children with functional abdominal pain: a comparison study of patients' and parents' perceptions. Pediatrics. 2006; 117 (1): 54–59.
9. Alaswad B., Toubas P.L., Grunow J.E. Environmental tobacco smoke exposure and gastroesophageal reflux in infants with apparent life-threatening events. J. Okla. State Med. Assoc. 1996; 89 (7): 233–237.
10. Kaltenbach T., Crockett S., Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch. Intern. Med. 2006; 166 (9): 965–971.
11. Rudolph C.D., Mazur L.J., Liptak G.S. et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 2001; 32 (Suppl. 2): 1–31.
12. Wendl B., Pfeiffer A., Pehl C., Schmidt T., Kaess H. Effect of decaffeination of coffee or tea on gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 1994; 8 (3): 283–287.
13. Murphy D.W., Castell D.O. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am. J. Gastroenterol. 1988; 83: 633–636.
14. Khan M., Santana J., Donnellan C., Preston C., Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst. Rev. 2007; 18 (2): CD003244.
15. van Pinxteren B., Numans M.E., Bonis P.A., Lau J. Short term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro–oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. 2006; 19 (3): CD002095.
16. Dalby-Payne J.R., Morris A.M., Craig J.C. Meta-analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastro–оesophageal reflux in children. J. Gastroenterol. Hepatol. 2003; 18 (2): 196-202.
17. Hassall E., Kerr W., El–Serag H.B. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J. Pediatr. 2007; 150 (3) 262–267.
18. Li J., Zhao J., Hamer-Maansson J.E., Andersson T. et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open label study. Clin. Ther. 2006; 28 (3): 419–427.
19. Gold B.D., Gunasekaran T., Tolia V. et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 2007; 45 (5): 520–529.
20. Lang L. FDA approves nexium for use in children ages 1–11 years. Gastroenterology. 2008; 134 (5): 1282.
21. Zhao J., Li J., Hamer–Maansson J.E. et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin. Ther. 2006; 28 (11): 1868–1876.
22. Omari T., Davidson G., Bondarov P. et al. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 2007; 45 (5): 530–537.
23. Бзарова Т.М., Щербаков П.Л., Алексеева Е.И. и др. Лечение гастроэзофагеальной рефлюксной болезни у детей с юношеским артритом. Вопросы современной педиатрии. 2007; 6 (4): 17–22.
24. Щербаков П.Л., Потапов А.С., Хавкин А.И. и др. Терапия кислотозависимых заболеваний органов пищеварения у детей. Вопросы современной педиатрии. 2005; 4 (1): 94–97.
25. Звягин А.А., Щербаков П.Л., Почивалов А.В., Кашников В.В. Эзомепразол (нексиум) в лечении функциональной диспепсии у детей по данным суточного рН-мониторирования. Бюллетень сибирской медицины. 2005; 2: 23–26.
26. Gralnek I.M., Dulai G.S., Fennerty M.B., Spiegel B.M. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin. Gastroenterol. Hepatol. 2006; 4 (12): 1452–1458.
27. Talley N.J., Armstrong D., Junghard O., Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment. Pharmacol. Ther. 2006; 24 (2): 371–376.
Рецензия
Для цитирования:
Сайгитов Р. ЭЗОМЕПРАЗОЛ В ЛЕЧЕНИИ ГАСТРОЭЗОФАГЕАЛЬНОЙ РЕФЛЮКСНОЙ БОЛЕЗНИ У ДЕТЕЙ И ПОДРОСТКОВ. Вопросы современной педиатрии. 2008;7(4):132-135.
For citation:
Saygitov R. ESOMEPRAZOL IN TREATMENT OF GASTROESOPHAGIAL REFLUX DISEASE IN CHILDREN AND ADOLESCENTS. Current Pediatrics. 2008;7(4):132-135.
Послать статью по эл. почте 
